Evogene (NASDAQ:EVGN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Evogene to post earnings of ($0.73) per share and revenue of $3.63 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Evogene Stock Down 0.7 %
Evogene stock opened at $1.41 on Thursday. The firm has a 50 day moving average price of $1.58 and a 200-day moving average price of $2.18. Evogene has a twelve month low of $1.20 and a twelve month high of $10.40. The company has a market capitalization of $7.56 million, a P/E ratio of -0.32 and a beta of 1.29.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Evogene in a report on Saturday, February 22nd. They set a “sell” rating on the stock.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- What is a Special Dividend?
- Buffett’s on the Sidelines – Should You Follow?
- How to Capture the Benefits of Dividend Increases
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
